Johnson & Johnson’s expects its vaccine candidate will protect against new strains of the virus that causes Covid-19, the company said Wednesday.
“We are closely monitoring newly emerging variations in the SARS-CoV-2 Spike protein. Previous research has generated cautious optimism that the mutations leading to SARS-CoV-2 viral diversity should not be an obstacle for the broadly protective SARS-CoV-2 vaccine candidates currently in development,” the company said in a statement to Bloomberg Law.
J&J’s vaccine is largely expected to be the next in line to receive clearance from the Food and Drug Administration for emergency use during the public health emergency,...